Likely to be Bristol Myers first Lag-3 phase 2/3 results this...

Likely to be Bristol Myers first Lag-3 phase 2/3 results this year:-

Study Type :Interventional (Clinical Trial)
Estimated Enrolment :700 participants
Allocation: Randomised Intervention
Modelarallel Assignment Maskingouble (Participant, Investigator)
Primary Purpose:Treatment
Title:A Randomised, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Actual Study Start Date :April 10, 2018
Estimated Primary Completion Date :May 24, 2021
Estimated Study Completion Date :March 16, 2023

Relatlimab (previously known as BMS-986016) is a cancer immunotherapy (anti-lag 3) being developed by Bristol-Myers Squibb (BMS).
The treatment has already shown benefit in melanoma patients and is also being tested in other cancers.
Nivolumab, sold under the brand name Opdivo, (BMS owned and marketed), is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, colon cancer, and liver cancer.